Preventing pediatric cardiomyopathy

A 2015 outlook

Paul F. Kantor, Jake A. Kleinman, Thomas D. Ryan, Ivan Wilmot, Warren A. Zuckerman, Linda J. Addonizio, Melanie D. Everitt, John L. Jefferies, Teresa M. Lee, Jeffrey A. Towbin, James D. Wilkinson, Steven E Lipshultz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cardiomyopathies in children encompass a broad range of diseases, both genetic and acquired, which manifest as a primary cardiac disorder or as a cardiomyopathy secondary to systemic disease. The burden of this group of disorders is substantial, and growing on a global scale. The availability of disease altering treatments is limited, and therefore a focused review on the prevention of cardiomyopathies is justified. In this review, we address the prevention of cardiomyopathy in children by dealing with the root causes of disease at a molecular, clinical and population level. Recent years have yielded promising returns in basic research related to gene-targeted therapy, specific anti-viral therapies and modification of the effects of cardiotoxic drugs. Much work remains to be done in the fields of vaccine development, public health and adoption of available treatments. Effective research in this field will require that diagnostic methods are both refined, and made available more broadly, from imaging to gene testing. Much of our knowledge today is derived from the use of registries, which have successfully catalogued the detailed phenotype of affected patients, and provided long-term longitudinal follow up of affected individuals.

Original languageEnglish (US)
Pages (from-to)321-339
Number of pages19
JournalExpert Review of Cardiovascular Therapy
Volume14
Issue number3
DOIs
StatePublished - Mar 3 2016
Externally publishedYes

Fingerprint

Cardiomyopathies
Pediatrics
Inborn Genetic Diseases
Research
Genetic Therapy
Registries
Therapeutics
Vaccines
Public Health
Phenotype
Pharmaceutical Preparations
Population
Genes

Keywords

  • Cardiomyopathy
  • Cardiotoxicity
  • Genetics
  • Myocarditis
  • Pediatric

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Kantor, P. F., Kleinman, J. A., Ryan, T. D., Wilmot, I., Zuckerman, W. A., Addonizio, L. J., ... Lipshultz, S. E. (2016). Preventing pediatric cardiomyopathy: A 2015 outlook. Expert Review of Cardiovascular Therapy, 14(3), 321-339. https://doi.org/10.1586/14779072.2016.1129899

Preventing pediatric cardiomyopathy : A 2015 outlook. / Kantor, Paul F.; Kleinman, Jake A.; Ryan, Thomas D.; Wilmot, Ivan; Zuckerman, Warren A.; Addonizio, Linda J.; Everitt, Melanie D.; Jefferies, John L.; Lee, Teresa M.; Towbin, Jeffrey A.; Wilkinson, James D.; Lipshultz, Steven E.

In: Expert Review of Cardiovascular Therapy, Vol. 14, No. 3, 03.03.2016, p. 321-339.

Research output: Contribution to journalArticle

Kantor, PF, Kleinman, JA, Ryan, TD, Wilmot, I, Zuckerman, WA, Addonizio, LJ, Everitt, MD, Jefferies, JL, Lee, TM, Towbin, JA, Wilkinson, JD & Lipshultz, SE 2016, 'Preventing pediatric cardiomyopathy: A 2015 outlook', Expert Review of Cardiovascular Therapy, vol. 14, no. 3, pp. 321-339. https://doi.org/10.1586/14779072.2016.1129899
Kantor PF, Kleinman JA, Ryan TD, Wilmot I, Zuckerman WA, Addonizio LJ et al. Preventing pediatric cardiomyopathy: A 2015 outlook. Expert Review of Cardiovascular Therapy. 2016 Mar 3;14(3):321-339. https://doi.org/10.1586/14779072.2016.1129899
Kantor, Paul F. ; Kleinman, Jake A. ; Ryan, Thomas D. ; Wilmot, Ivan ; Zuckerman, Warren A. ; Addonizio, Linda J. ; Everitt, Melanie D. ; Jefferies, John L. ; Lee, Teresa M. ; Towbin, Jeffrey A. ; Wilkinson, James D. ; Lipshultz, Steven E. / Preventing pediatric cardiomyopathy : A 2015 outlook. In: Expert Review of Cardiovascular Therapy. 2016 ; Vol. 14, No. 3. pp. 321-339.
@article{6cd867460697424b91e95d6c68332117,
title = "Preventing pediatric cardiomyopathy: A 2015 outlook",
abstract = "Cardiomyopathies in children encompass a broad range of diseases, both genetic and acquired, which manifest as a primary cardiac disorder or as a cardiomyopathy secondary to systemic disease. The burden of this group of disorders is substantial, and growing on a global scale. The availability of disease altering treatments is limited, and therefore a focused review on the prevention of cardiomyopathies is justified. In this review, we address the prevention of cardiomyopathy in children by dealing with the root causes of disease at a molecular, clinical and population level. Recent years have yielded promising returns in basic research related to gene-targeted therapy, specific anti-viral therapies and modification of the effects of cardiotoxic drugs. Much work remains to be done in the fields of vaccine development, public health and adoption of available treatments. Effective research in this field will require that diagnostic methods are both refined, and made available more broadly, from imaging to gene testing. Much of our knowledge today is derived from the use of registries, which have successfully catalogued the detailed phenotype of affected patients, and provided long-term longitudinal follow up of affected individuals.",
keywords = "Cardiomyopathy, Cardiotoxicity, Genetics, Myocarditis, Pediatric",
author = "Kantor, {Paul F.} and Kleinman, {Jake A.} and Ryan, {Thomas D.} and Ivan Wilmot and Zuckerman, {Warren A.} and Addonizio, {Linda J.} and Everitt, {Melanie D.} and Jefferies, {John L.} and Lee, {Teresa M.} and Towbin, {Jeffrey A.} and Wilkinson, {James D.} and Lipshultz, {Steven E}",
year = "2016",
month = "3",
day = "3",
doi = "10.1586/14779072.2016.1129899",
language = "English (US)",
volume = "14",
pages = "321--339",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Preventing pediatric cardiomyopathy

T2 - A 2015 outlook

AU - Kantor, Paul F.

AU - Kleinman, Jake A.

AU - Ryan, Thomas D.

AU - Wilmot, Ivan

AU - Zuckerman, Warren A.

AU - Addonizio, Linda J.

AU - Everitt, Melanie D.

AU - Jefferies, John L.

AU - Lee, Teresa M.

AU - Towbin, Jeffrey A.

AU - Wilkinson, James D.

AU - Lipshultz, Steven E

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Cardiomyopathies in children encompass a broad range of diseases, both genetic and acquired, which manifest as a primary cardiac disorder or as a cardiomyopathy secondary to systemic disease. The burden of this group of disorders is substantial, and growing on a global scale. The availability of disease altering treatments is limited, and therefore a focused review on the prevention of cardiomyopathies is justified. In this review, we address the prevention of cardiomyopathy in children by dealing with the root causes of disease at a molecular, clinical and population level. Recent years have yielded promising returns in basic research related to gene-targeted therapy, specific anti-viral therapies and modification of the effects of cardiotoxic drugs. Much work remains to be done in the fields of vaccine development, public health and adoption of available treatments. Effective research in this field will require that diagnostic methods are both refined, and made available more broadly, from imaging to gene testing. Much of our knowledge today is derived from the use of registries, which have successfully catalogued the detailed phenotype of affected patients, and provided long-term longitudinal follow up of affected individuals.

AB - Cardiomyopathies in children encompass a broad range of diseases, both genetic and acquired, which manifest as a primary cardiac disorder or as a cardiomyopathy secondary to systemic disease. The burden of this group of disorders is substantial, and growing on a global scale. The availability of disease altering treatments is limited, and therefore a focused review on the prevention of cardiomyopathies is justified. In this review, we address the prevention of cardiomyopathy in children by dealing with the root causes of disease at a molecular, clinical and population level. Recent years have yielded promising returns in basic research related to gene-targeted therapy, specific anti-viral therapies and modification of the effects of cardiotoxic drugs. Much work remains to be done in the fields of vaccine development, public health and adoption of available treatments. Effective research in this field will require that diagnostic methods are both refined, and made available more broadly, from imaging to gene testing. Much of our knowledge today is derived from the use of registries, which have successfully catalogued the detailed phenotype of affected patients, and provided long-term longitudinal follow up of affected individuals.

KW - Cardiomyopathy

KW - Cardiotoxicity

KW - Genetics

KW - Myocarditis

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=84959085367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959085367&partnerID=8YFLogxK

U2 - 10.1586/14779072.2016.1129899

DO - 10.1586/14779072.2016.1129899

M3 - Article

VL - 14

SP - 321

EP - 339

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 3

ER -